This inter-institutional study assesses genomic risk in breast and ovarian cancer, indicating the value of genetic testing for high-risk individuals.
Key Points
This study aims to identify the genomic profile of patients with breast or ovarian cancer and evaluate the clinical impact of genetic testing on management decisions.
Included individuals diagnosed with breast and/or ovarian cancer referred for genetic evaluation
Participants underwent genetic testing under a specific inter-institutional protocol from 2013 to 2020
Included a comprehensive review of clinical genetic evaluations and testing outcomes.
1577 patients recruited, with 99.3% being females diagnosed with breast or ovarian cancer
13.4% of individuals had a pathogenic or likely pathogenic variant in an actionable gene
72% of patients received high-risk management recommendations over a 10-year follow-up.